Immunotherapy + TACE +/- Lenvatinib for Liver Cancer
(EMERALD-3 Trial)
Trial Summary
Do I have to stop taking my current medications for this trial?
The trial information does not specify if you need to stop taking your current medications. Please consult with the trial coordinators for more details.
Do I need to stop my current medications for this trial?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the idea that Immunotherapy + TACE +/- Lenvatinib for Liver Cancer is an effective treatment?
The available research shows that the combination of tremelimumab and durvalumab, which are part of the immunotherapy treatment, has been approved for treating liver cancer. In a study called HIMALAYA, this combination was shown to help patients live longer compared to another drug called sorafenib. Specifically, patients lived for about 16.4 months on average with the combination treatment, compared to 13.8 months with sorafenib. This suggests that the immunotherapy combination is more effective than some existing treatments for liver cancer.12345
What data supports the effectiveness of the drug combination of Durvalumab and Tremelimumab for liver cancer?
The combination of Durvalumab and Tremelimumab has been shown to improve overall survival in patients with unresectable hepatocellular carcinoma (a type of liver cancer) compared to the drug sorafenib, as demonstrated in the HIMALAYA study. This combination was approved by the FDA based on these results, indicating its effectiveness in treating this type of liver cancer.12345
What safety data exists for the treatment of liver cancer with Immunotherapy + TACE +/- Lenvatinib?
Is the drug combination of Durvalumab, Lenvatinib, and Tremelimumab promising for liver cancer?
Yes, the combination of these drugs shows promise for treating liver cancer. Studies suggest that using Lenvatinib with other treatments like Durvalumab and Tremelimumab can be effective, especially for cases where surgery isn't an option. This combination may improve the treatment's effectiveness against the cancer.1112131415
How is the treatment with Durvalumab, Lenvatinib, and Tremelimumab for liver cancer different from other treatments?
This treatment combines immunotherapy (using the body's immune system to fight cancer) with a drug called Lenvatinib and a procedure called TACE (which blocks blood supply to the tumor), offering a unique approach for liver cancer that cannot be removed by surgery. It is different because it combines multiple methods to potentially enhance effectiveness against the cancer.1112131415
What is the purpose of this trial?
A global study to evaluate transarterial chemoembolization (TACE) in combination with durvalumab, tremelimumab and lenvatinib therapy in patients with locoregional hepatocellular carcinoma
Eligibility Criteria
This trial is for adults with hepatocellular carcinoma (a type of liver cancer) that can't be removed by surgery but can be treated with TACE. Participants should have no cancer outside the liver, an ECOG performance status of 0 or 1 indicating they are fully active or restricted in physically strenuous activity only, and a Child Pugh score class A showing mild liver disease.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Tremelimumab, Durvalumab, and Lenvatinib in combination with Transarterial Chemoembolization (TACE) or TACE alone
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Durvalumab
- Lenvatinib
- Transarterial Chemoembolization (TACE)
- Tremelimumab
Durvalumab is already approved in European Union, United States, Japan for the following indications:
- Locally advanced, unresectable non-small cell lung cancer (NSCLC)
- Extensive-stage small cell lung cancer (ES-SCLC)
- Limited-stage small cell lung cancer (LS-SCLC)
- Locally advanced or metastatic urothelial carcinoma
- Not specified in provided sources
Find a Clinic Near You
Who Is Running the Clinical Trial?
AstraZeneca
Lead Sponsor
Sir Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Dr. Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology